Hayward Marshall A. 4

What Happened
Marshall A. Hayward, Chief Scientific Officer and a director of Jupiter Neurosciences (JUNS), reported exercising or converting derivative securities (Form 4 code M) into 1,014,195 shares of common stock across transactions on 2025-06-02 and 2026-03-02. The filings show the derivative conversions reported with a $0.00 per-share consideration (i.e., no cash paid/received on the Form 4 lines), indicating conversion/exercise of vested awards or options into common shares rather than an open-market sale or purchase.

Key Details

• Transactions and amounts:
  • 2025-06-02: converted 389,793 shares (reported as exercise/conversion, $0.00 per share)
  • 2025-06-02: converted 399,402 shares (reported as exercise/conversion, $0.00 per share)
  • 2026-03-02: converted 225,000 shares (reported as exercise/conversion, $0.00 per share)
  • Total converted: 1,014,195 shares
• Transaction code: M = exercise/conversion of a derivative security.
• Footnotes from the filing:
  • F1: These securities convert into common stock on a one-for-one basis.
  • F2: Some awards vested on expiration of the IPO lock-up period.
  • F3: The shares underlying an option vested 100% on January 1, 2016.
• Shares owned after transaction: not specified in the excerpt provided.
• Filing timeliness: Report filed 2026-07-13 for transactions dated 2025-06-02 and 2026-03-02 — the 2025 transaction is reported over a year after the transaction date, indicating a late filing.

Context
These filings reflect conversion/exercise of derivative securities into common stock (not open-market purchases or sales). The $0.00 per-share disposition lines and the footnotes suggest these were vesting-related conversions (e.g., vested awards or options converting one-for-one), not cashless exercises that generated immediate sale proceeds. Because no open-market sale occurred, these entries do not by themselves signal a bullish or bearish trade intent; they document the issuance/transfer of shares resulting from vested derivatives.